572 related articles for article (PubMed ID: 26554850)
1. Tumor microenvironment (TME)-driven immune suppression in B cell malignancy.
Nicholas NS; Apollonio B; Ramsay AG
Biochim Biophys Acta; 2016 Mar; 1863(3):471-482. PubMed ID: 26554850
[TBL] [Abstract][Full Text] [Related]
2. Microenvironment Remodeling and Subsequent Clinical Implications in Diffuse Large B-Cell Histologic Variant of Richter Syndrome.
Augé H; Notarantonio AB; Morizot R; Quinquenel A; Fornecker LM; Hergalant S; Feugier P; Broséus J
Front Immunol; 2020; 11():594841. PubMed ID: 33381116
[TBL] [Abstract][Full Text] [Related]
3. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
[TBL] [Abstract][Full Text] [Related]
4. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.
Ten Hacken E; Burger JA
Biochim Biophys Acta; 2016 Mar; 1863(3):401-413. PubMed ID: 26193078
[TBL] [Abstract][Full Text] [Related]
5. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
6. Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review.
Taghiloo S; Asgarian-Omran H
Eur J Haematol; 2024 Jul; 113(1):4-15. PubMed ID: 38698678
[TBL] [Abstract][Full Text] [Related]
7. Programming the immune checkpoint to treat hematologic malignancies.
Vick E; Mahadevan D
Expert Opin Investig Drugs; 2016 Jul; 25(7):755-70. PubMed ID: 27070269
[TBL] [Abstract][Full Text] [Related]
8. The tumor microenvironment shapes hallmarks of mature B-cell malignancies.
Shain KH; Dalton WS; Tao J
Oncogene; 2015 Sep; 34(36):4673-82. PubMed ID: 25639873
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas.
Pascual M; Mena-Varas M; Robles EF; Garcia-Barchino MJ; Panizo C; Hervas-Stubbs S; Alignani D; Sagardoy A; Martinez-Ferrandis JI; Bunting KL; Meier S; Sagaert X; Bagnara D; Guruceaga E; Blanco O; Celay J; Martínez-Baztan A; Casares N; Lasarte JJ; MacCarthy T; Melnick A; Martinez-Climent JA; Roa S
Blood; 2019 May; 133(22):2401-2412. PubMed ID: 30975638
[TBL] [Abstract][Full Text] [Related]
10. Dual effect of DLBCL-derived EXOs in lymphoma to improve DC vaccine efficacy in vitro while favor tumorgenesis in vivo.
Chen Z; You L; Wang L; Huang X; Liu H; Wei JY; Zhu L; Qian W
J Exp Clin Cancer Res; 2018 Aug; 37(1):190. PubMed ID: 30103789
[TBL] [Abstract][Full Text] [Related]
11. Bone Marrow Lymphoid Niche Adaptation to Mature B Cell Neoplasms.
Dumontet E; Mancini SJC; Tarte K
Front Immunol; 2021; 12():784691. PubMed ID: 34956214
[TBL] [Abstract][Full Text] [Related]
12. Metabolic Regulation of Tregs in Cancer: Opportunities for Immunotherapy.
Wang H; Franco F; Ho PC
Trends Cancer; 2017 Aug; 3(8):583-592. PubMed ID: 28780935
[TBL] [Abstract][Full Text] [Related]
13. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome.
Wang Y; Sinha S; Wellik LE; Secreto CR; Rech KL; Call TG; Parikh SA; Kenderian SS; Muchtar E; Hayman SR; Koehler AB; Van Dyke DL; Leis JF; Slager SL; Dong H; Kay NE; He R; Ding W
Blood Cancer J; 2021 May; 11(5):86. PubMed ID: 33972504
[TBL] [Abstract][Full Text] [Related]
14. Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy.
Apollonio B; Ioannou N; Papazoglou D; Ramsay AG
Front Oncol; 2021; 11():626818. PubMed ID: 33842331
[TBL] [Abstract][Full Text] [Related]
15. The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies.
Petitprez F; Meylan M; de Reyniès A; Sautès-Fridman C; Fridman WH
Front Immunol; 2020; 11():784. PubMed ID: 32457745
[TBL] [Abstract][Full Text] [Related]
16. The chronic lymphocytic leukemia microenvironment: Beyond the B-cell receptor.
Choi MY; Kashyap MK; Kumar D
Best Pract Res Clin Haematol; 2016 Mar; 29(1):40-53. PubMed ID: 27742071
[TBL] [Abstract][Full Text] [Related]
17. Beyond bystanders: Myeloid cells in chronic lymphocytic leukemia.
Hanna BS; Öztürk S; Seiffert M
Mol Immunol; 2019 Jun; 110():77-87. PubMed ID: 29173971
[TBL] [Abstract][Full Text] [Related]
18. Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.
Luheshi NM; Coates-Ulrichsen J; Harper J; Mullins S; Sulikowski MG; Martin P; Brown L; Lewis A; Davies G; Morrow M; Wilkinson RW
Oncotarget; 2016 Apr; 7(14):18508-20. PubMed ID: 26918344
[TBL] [Abstract][Full Text] [Related]
19. PD-1 Blockade Can Restore Functions of T-Cells in Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma In Vitro.
Quan L; Chen X; Liu A; Zhang Y; Guo X; Yan S; Liu Y
PLoS One; 2015; 10(9):e0136476. PubMed ID: 26361042
[TBL] [Abstract][Full Text] [Related]
20. Galectin 3 as a guardian of the tumor microenvironment.
Ruvolo PP
Biochim Biophys Acta; 2016 Mar; 1863(3):427-437. PubMed ID: 26264495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
